Related Experiment Video
Updated: Aug 7, 2025
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
Artificial Intelligence-Based Computational Screening and Functional Assays Identify Candidate Small Molecule
Kathleen Molyneaux1, Christian Laggner2, Susann M Brady-Kalnay1
1Department of Molecular Biology & Microbiology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106-4960, USA.
Abstract:
PTPmu (PTPµ) is a member of the receptor protein tyrosine phosphatase IIb family that participates in cell-cell adhesion and signaling. PTPmu is proteolytically downregulated in glioblastoma (glioma), and the resulting extracellular and intracellular fragments are believed to stimulate cancer cell growth and/or migration. Therefore, drugs targeting these fragments may have therapeutic potential. Here, we used the AtomNet® platform, the first deep learning neural network for drug design and discovery, to screen a molecular library of several million compounds and identified 76 candidates predicted to interact with a groove between the MAM and Ig extracellular domains required for PTPmu-mediated cell adhesion. These candidates were screened in two cell-based assays: PTPmu-dependent aggregation of Sf9 cells and a tumor growth assay where glioma cells grow in three-dimensional spheres. Four compounds inhibited PTPmu-mediated aggregation of Sf9 cells, six compounds inhibited glioma sphere formation/growth, while two priority compounds were effective in both assays. The stronger of these two compounds inhibited PTPmu aggregation in Sf9 cells and inhibited glioma sphere formation down to 25 micromolar. Additionally, this compound was able to inhibit the aggregation of beads coated with an extracellular fragment of PTPmu, directly demonstrating an interaction. This compound presents an interesting starting point for the development of PTPmu-targeting agents for treating cancer including glioblastoma.
Insights
Researchers identified potential drug candidates targeting PTPmu (receptor protein tyrosine phosphatase mu) fragments, which are implicated in glioblastoma growth. One compound effectively inhibited PTPmu aggregation and glioma sphere formation, showing therapeutic promise.
Area of Science:
- Biochemistry
- Oncology
- Drug Discovery
Background:
- PTPmu (receptor protein tyrosine phosphatase mu) is involved in cell adhesion and signaling.
- Proteolytic downregulation of PTPmu in glioblastoma leads to fragments that may promote cancer progression.
- Targeting these PTPmu fragments offers a potential therapeutic strategy for glioblastoma.
Purpose of the Study:
- To identify novel compounds that interact with PTPmu fragments.
- To evaluate the efficacy of identified compounds in inhibiting PTPmu-mediated cell adhesion and glioblastoma growth.
Main Methods:
- Utilized AtomNet®, a deep learning platform, to screen millions of compounds for predicted interaction with PTPmu.
- Conducted cell-based assays to assess PTPmu-dependent cell aggregation and glioma sphere formation.
- Validated compound interactions with PTPmu extracellular fragments.
Main Results:
- Identified 76 candidate compounds predicted to interact with PTPmu.
- Four compounds inhibited PTPmu-mediated Sf9 cell aggregation; six inhibited glioma sphere formation.
- Two compounds showed efficacy in both assays, with one notably inhibiting PTPmu aggregation and glioma growth down to 25 micromolar.
- The lead compound demonstrated direct interaction with PTPmu extracellular fragments.
Conclusions:
- The identified lead compound is a promising starting point for developing PTPmu-targeting cancer therapeutics.
- This approach offers a novel strategy for treating glioblastoma and other cancers involving PTPmu dysregulation.
